Recent Quotes (30 days)

You have no recent quotes
chg | %

Med Biogene Inc  

(Public, CVE:MBI)   Watch this stock  
Find more results for MBI
0.0600
+0.0050 (9.09%)
Delayed:   1:51PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.06
52 week 0.03 - 0.12
Open 0.05
Vol / Avg. 106,400.00/95,088.00
Mkt cap 5.05M
P/E     -
Div/yield     -
EPS 0.00
Shares 83.93M
Beta 2.87
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.73% -251.05%
Return on average equity -90.38% -372.86%
CDP Score - -

Address

598 East, Kent Avenue South
VANCOUVER, BC V5X 4V6
Canada
+1-800-6413593 (Phone)
+1-888-6462531 (Fax)

Website links

Description

Med BioGene Inc. (MBI) is a Canadian-based life science company. The Company is engaged in the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. It�s focus is on managing the license and rights to GeneFx Lung (formerly, LungExpress Dx), a gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung.

Officers and directors

Erinn B. Broshko Executive Chairman of the Board
Iain Weir-Jones Ph.D. Chief Executive Officer
Ibrahim Ghobrial Chief Financial Officer
Shumsheer Sidhu Director
Heiner Dreismann Ph.D. Independent Director
Age: 61
Dennis L. Grimaud Independent Director
Age: 64
Kevin K. Rooney Independent Director